In vitro Investigation of the Effect of Anti-inflammatory and Analgesic Drugs on Measurement of Tumor Markers

Page: [273 - 277] Pages: 5

  • * (Excluding Mailing and Handling)

Abstract

Background: It has been shown that some drugs used as parenteral affect biochemical measurements. Anti-inflammatory and analgesic drugs may also have the potential to affect measurement methods.

Objective: The aim of the study was to investigate the effects of seven different anti-inflammatory and analgesic pharmacological agents commonly used in wards and intensive care units on thyroglobulin, CA125, CA15-3, CA19-9, CEA, PSA and total HCG tests measured by immunoassay technique.

Methods: The study was performed using hormone control material (BioRad Lyphocheck Immunoassay Plus Control) in the PETINIA immunoassay method (Siemens, Atellica, USA). 20 μL of tenoxicam, dexamethasone, methylprednisolone, paracetamol, diclofenac sodium, dexketoprofen, and metamizole sodium were added into 180 μL of the control solution, respectively. After vortexing the sample, it was incubated for 20 minutes at room temperature. Thyroglobulin, CA125, CA15- 3, CA19-9, CEA, total PSA and total HCG tests were studied from the control sample. The study was re-performed by adding 20 μL of distilled water. The measurements were repeated 3 times, and the mean values were recorded. Percentage deviation rates from the target value were calculated.

Results: Metamizole sodium led to negative interference in the CA 19-9, total HCG, CA 125, CEA, total PSA and CA15-3 at a rate of -42.1%, -24.62%, -24.34%, -23.66%, -14.33%, and -13.91%, respectively. With the administration of metamizole sodium, the only positive interference was determined at a rate of 6.02% in thyroglobulin. Paracetamol-induced maximum deviation was calculated at the rate of -26.41% in CA 19-9. CA 19-9 deviated -12.22% from diclofenac sodium and - 22.41% from dexketoprofen. With methylprednisolone administration, positive interference was detected at a rate of 14.46% in thyroglobulin and negative interference at a rate of -12% in total PSA. The highest deviation due to dexketoprofen was seen in CA 19-9 at a rate of -22.41%.

Conclusion: This study demonstrated the potential of anti-inflammatory, analgesic, and antipyretic agents to affect tumor marker measurements. Especially in the follow-up of cancer patients, antiinflammatory interference may increase the likelihood of malpractice by causing erroneous clinical evaluations.

Keywords: Anti-inflammatory drugs, analgesics, CA125, CA15-3, CA19-9, CEA, total PSA, false result.

[1]
Kollef MH. Optimizing antibiotic therapy in the intensive care unit setting. Crit Care 2001; 5(4): 189-95.
[http://dx.doi.org/10.1186/cc1022] [PMID: 11511331]
[2]
Ali M, Naureen H, Tariq MH, et al. Rational use of antibiotics in an intensive care unit: A retrospective study of the impact on clinical outcomes and mortality rate. Infect Drug Resist 2019; 12: 493-9.
[http://dx.doi.org/10.2147/IDR.S187836] [PMID: 30881054]
[3]
Johansson SG, Adédoyin J, van Hage M, Grönneberg R, Nopp A. False-positive penicillin immunoassay: An unnoticed common problem. J Allergy Clin Immunol 2013; 132(1): 235-7.
[http://dx.doi.org/10.1016/j.jaci.2012.11.017] [PMID: 23270810]
[4]
Weaver K, Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception 1999; 59(2): 71-8.
[http://dx.doi.org/10.1016/S0010-7824(99)00009-8] [PMID: 10361620]
[5]
Swain RR, Briggs SL. Positive interference with the Jaffé reaction by cephalosporin antibiotics. Clin Chem 1977; 23(7): 1340-2.
[http://dx.doi.org/10.1093/clinchem/23.7.1340] [PMID: 872385]
[6]
Marinova M, Artusi C, Brugnolo L, Antonelli G, Zaninotto M, Plebani M. Immunosuppressant therapeutic drug monitoring by LC-MS/MS: Workflow optimization through automated processing of whole blood samples. Clin Biochem 2013; 46(16-17): 1723-7.
[http://dx.doi.org/10.1016/j.clinbiochem.2013.08.013] [PMID: 24012696]
[7]
Koster RA, Alffenaar J-WC, Greijdanus B, Uges DR. Fast LC-MS/MS analysis of tacrolimus, sirolimus, everolimus and cyclosporin A in dried blood spots and the influence of the hematocrit and immunosuppressant concentration on recovery. Talanta 2013; 115: 47-54.
[http://dx.doi.org/10.1016/j.talanta.2013.04.027] [PMID: 24054560]
[8]
Gönel A, Koyuncu I. False immunosuppressant measurement by LC-MS/MS method due to radiopaque agents. Comb Chem High Throughput Screen 2019; 22(2): 129-34.
[http://dx.doi.org/10.2174/1386207322666190418125307] [PMID: 31038053]
[9]
Dasgupta A. Biotin and other interferences in immunoassays: A concise guide. Elsevier 2019.
[10]
Tate J, Ward G. Interferences in immunoassay. Clin Biochem Rev 2004; 25(2): 105-20.
[PMID: 18458713]
[11]
Wild D. The immunoassay handbook: Theory and applications of ligand binding, ELISA and related techniques.In: Newnes. Elsevier 2013.
[12]
Kricka LJ. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999; 45(7): 942-56.
[http://dx.doi.org/10.1093/clinchem/45.7.942] [PMID: 10388468]
[13]
Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990; 85(4): 350-5.
[PMID: 2183589]
[14]
Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancre-atic cancer. Eur J Surg Oncol 2007; 33(3): 266-70.
[15]
Matsumoto S, Mori T, Miyoshi J, et al. Huge splenic epidermoid cyst with elevation of serum CA19-9 level. JMI 2015; 62(1-2): 89-92.
[http://dx.doi.org/10.2152/jmi.62.89] [PMID: 25817291]
[16]
Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987; 47(20): 5501-3.
[PMID: 3308077]
[17]
Goetz M, Steen PD. False elevation of CA 19-9 levels in a patient with a history of pancreatic cancer. Am J Gastroenterol 1997; 92(8): 1390-1.
[PMID: 9260821]
[18]
Monaghan PJ, Leonard MB, Neithercut WD, Raraty MG, Sodi R. False positive carbohydrate antigen 19-9 (CA19-9) results due to a low-molecular weight interference in an apparently healthy male. Clin Chim Acta 2009; 406(1-2): 41-4.
[19]
Krasowski MD, Drees D, Morris CS, Maakestad J, Blau JL, Ekins S. Cross-reactivity of steroid hormone immunoassays: Clinical significance and two-dimensional molecular similarity prediction. BMC Clin Pathol 2014; 14(1): 33.
[http://dx.doi.org/10.1186/1472-6890-14-33] [PMID: 25071417]
[20]
Astarita G, Gutiérrez S, Kogovsek N, et al. False positive in the measurement of thyroglobulin induced by rheumatoid factor. Clin Chim Acta 2015; 447: 43-6.
[21]
White GH, Tideman PA. Heterophilic antibody interference with CARDIAC T quantitative rapid assay. Clin Chem 2002; 48(1): 201-3.
[http://dx.doi.org/10.1093/clinchem/48.1.201] [PMID: 11751561]
[22]
Wu AH, Smith A, Christenson RH, Murakami MM, Apple FS. Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction. Clin Chim Acta 2004; 346(2): 211-9.
[http://dx.doi.org/10.1016/j.cccn.2004.03.036] [PMID: 15256323]
[23]
Avouac J, Meune C, Chenevier-Gobeaux C, et al. Inflammation and disease activity are associated with high circulating cardiac markers in rheumatoid arthritis independently of traditional cardiovascular risk factors. J Rheumatol 2014; 41(2): 248-55.
[http://dx.doi.org/10.3899/jrheum.130713] [PMID: 24334650]
[24]
García-González E, Aramendía M, Álvarez-Ballano D, Trincado P, Rello L. Serum sample containing endogenous antibodies interfering with multiple hormone immunoassays. Laboratory strategies to detect interference. Pract Lab Med 2015; 4: 1-10.
[http://dx.doi.org/10.1016/j.plabm.2015.11.001] [PMID: 28856186]